165 related articles for article (PubMed ID: 34462939)
1. COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
Del Poeta G; Bomben R; Polesel J; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Postorino M; Laureana R; Pasqualone G; Steffan A; Gentile M; Zucchetto A; Gattei V
Hematol Oncol; 2021 Dec; 39(5):712-714. PubMed ID: 34462939
[No Abstract] [Full Text] [Related]
2. Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.
Tadmor T; Benjamini O; Braester A; Rahav G; Rokach L
Leukemia; 2021 Sep; 35(9):2727-2730. PubMed ID: 34376803
[No Abstract] [Full Text] [Related]
3. mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
Molica S; Giannarelli D; Montserrat E
Eur J Haematol; 2022 Mar; 108(3):264-267. PubMed ID: 34856031
[No Abstract] [Full Text] [Related]
4. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia.
Parry H; McIlroy G; Bruton R; Ali M; Stephens C; Damery S; Otter A; McSkeane T; Rolfe H; Faustini S; Wall N; Hillmen P; Pratt G; Paneesha S; Zuo J; Richter A; Moss P
Blood Cancer J; 2021 Jul; 11(7):136. PubMed ID: 34330895
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
Roeker LE; Knorr DA; Thompson MC; Nivar M; Lebowitz S; Peters N; Deonarine I; Momotaj S; Sharan S; Chanlatte V; Hampton B; Butala L; Amato L; Richford A; Lunkenheimer J; Battiato K; Laudati C; Mato AR
Leukemia; 2021 Sep; 35(9):2703-2705. PubMed ID: 33986431
[No Abstract] [Full Text] [Related]
6. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T
Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068
[TBL] [Abstract][Full Text] [Related]
7. Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
Chowdhury O; Bruguier H; Mallett G; Sousos N; Crozier K; Allman C; Eyre D; Lumley S; Strickland M; Karali CS; Murphy L; Sternberg A; Jeffery K; Mead AJ; Peniket A; Psaila B
Br J Haematol; 2021 Sep; 194(6):1010-1015. PubMed ID: 34132395
[No Abstract] [Full Text] [Related]
8. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
Morawska M
Eur J Haematol; 2022 Feb; 108(2):91-98. PubMed ID: 34717004
[TBL] [Abstract][Full Text] [Related]
9. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
[No Abstract] [Full Text] [Related]
10. Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
Fox TA; Kirkwood AA; Enfield L; O'Reilly M; Arulogun S; D'Sa S; O'Nions J; Kavi J; Vitsaras E; Townsend W; Burns SO; Gohil SH; Cwynarski K; Thomson KJ; Noursadeghi M; Heyderman RS; Rampling T; Ardeshna KM; McCoy LE; Morris EC
Br J Haematol; 2021 Dec; 195(5):706-709. PubMed ID: 34545952
[No Abstract] [Full Text] [Related]
11. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
Cevik M; Grubaugh ND; Iwasaki A; Openshaw P
Cell; 2021 Sep; 184(20):5077-5081. PubMed ID: 34534444
[TBL] [Abstract][Full Text] [Related]
12. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
13. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma.
Lim SH; Campbell N; Johnson M; Joseph-Pietras D; Collins GP; O'Callaghan A; Fox CP; Ahearne M; Johnson PWM; Goldblatt D; Davies AJ
Lancet Haematol; 2021 Aug; 8(8):e542-e544. PubMed ID: 34224667
[No Abstract] [Full Text] [Related]
14. Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines.
Kozak KE; Ouyang L; Derkach A; Sherman A; McCall SJ; Famulare C; Chervin J; Daley RJ; Morjaria S; Mauro MJ; Rampal RK
Leukemia; 2021 Dec; 35(12):3578-3580. PubMed ID: 34741117
[No Abstract] [Full Text] [Related]
15. Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report.
Cuneo A; Rigolin GM; Coscia M; Quaresmini G; Scarfò L; Mauro FR; Motta M; Quaglia FM; Trentin L; Ferrario A; Laurenti L; Reda G; Ferrari A; Pietrasanta D; Sportoletti P; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; Farina L; Del Poeta G; Varettoni M; Chiurazzi F; Marasca R; Malerba L; Ibatici A; Tisi MC; Stefoni V; Leone M; Baratè C; Olivieri J; Murru R; Gentile M; Sanna A; Gozzetti A; Gattei V; Gottardi D; Derenzini E; Levato L; Orsucci L; Penna G; Chiarenza A; Foà R
Hematol Oncol; 2021 Oct; 39(4):570-574. PubMed ID: 34258787
[No Abstract] [Full Text] [Related]
16. Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients.
Blixt L; Bogdanovic G; Buggert M; Gao Y; Hober S; Healy K; Johansson H; Kjellander C; Mravinacova S; Muschiol S; Nilsson P; Palma M; Pin E; Smith CIE; Stromberg O; Sällberg Chen M; Zain R; Hansson L; Österborg A
Leukemia; 2022 Feb; 36(2):476-481. PubMed ID: 34564699
[TBL] [Abstract][Full Text] [Related]
17. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming.
Hansen CB; Jarlhelt I; Hasselbalch RB; Hamm SR; Fogh K; Pries-Heje MM; Møller DL; Heftdal LD; Pérez-Alós L; Sørensen E; Larsen MAH; Skjoedt MO; Ostrowski SR; Frikke-Schmidt R; Bayarri-Olmos R; Hilsted LM; Bundgaard H; Nielsen SD; Iversen KK; Garred P
J Intern Med; 2021 Dec; 290(6):1272-1274. PubMed ID: 34237190
[No Abstract] [Full Text] [Related]
18. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
[TBL] [Abstract][Full Text] [Related]
19. Scent of a vaccine.
Lund FE; Randall TD
Science; 2021 Jul; 373(6553):397-399. PubMed ID: 34437109
[No Abstract] [Full Text] [Related]
20. The long road.
Cohen J
Science; 2021 Feb; 371(6531):768-772. PubMed ID: 33602838
[No Abstract] [Full Text] [Related]
[Next] [New Search]
